Golden Meditech Holdings Limited China's leading integrated healthcare enterprise, has announced that the Group will acquire the remaining interests in the Group's Chinese herbal medicine business for a total consideration of HK$90 million in shares. Upon completion of the transaction, the Chinese herbal medicine business will become wholly-owned by the Group.
The Chinese herbal medicine business is principally engaged in the research and development, production and distribution of Chinese herbal medicines in China and overseas, as well as the operation of a Chinese herbal medicine retail chain in the United Kingdom and Ireland. It also owns and operates an approved GMP production facility, spanning across 58,000 square meters, in Municipal Shanghai.
Kam Yuen, chairman of the group, commented on the timing of the transaction, said, “It is a timely opportunity for us to acquire the remaining interests along with a sizable plot of land in a prime location in Shanghai at a very reasonable price.”
As the Chinese herbal medicine industry in Europe is at the brink of recovery, the Group will assemble a new management team to improve its operations, efficiency, and scale of operations leveraging the Group's resources in China.
Golden Meditech Holdings Limited is the first medical device enterprise that was publicly listed outside of the PRC on the Stock Exchange of Hong Kong Limited (HKEx) and is a first-mover in China, having established dominant positions in medical devices and healthcare services markets over the years, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities.